HEART EYE DIAGNOSTICS LIMITED

What HEART EYE DIAGNOSTICS LIMITED does

Heart Eye Diagnostics Limited (operating as HeartEye) is a UK-based private medical AI company that develops and distributes Dr. Noon, a cloud-based AI retinal screening platform that delivers dual insights from a single routine fundus photograph: cardiovascular disease (CVD) risk assessment and retinal disease detection. The platform comprises two principal modules, Dr. Noon HEART (CACS-aligned CVD risk stratification into Low/Moderate/High bands with 5-year predictive horizon) and Dr. Noon EYE (detection of glaucoma suspect indicators, AMD, diabetic retinopathy, and cataracts at 96% accuracy comparable to ophthalmologists), plus distinct editions for healthcare professionals and eye care professionals.

The underlying technology is a deep-learning system trained on hundreds of thousands of retinal images from UK Biobank and CMERC-HI cohorts across diverse ethnicities, validated in 50+ peer-reviewed publications including The Lancet Digital Health and JAMIA. The platform is CE-marked and MHRA-approved as a medical device, GDPR and HIPAA compliant, and designed to integrate with practitioners' existing fundus cameras without new equipment, specialist staff, or radiation exposure, returning results in approximately one minute.

HeartEye monetises through a mix of subscription and per-screening fees, with quote-based monthly pricing for professional tiers. Go-to-market combines a self-serve cloud product-led funnel (cvd.eyeexam.ai), inside sales with phone, WhatsApp, and email support, and channel distribution through optometrists and primary care networks in the United Kingdom. The company is small (1-10 employees), based in London/Edgware, has not disclosed funding rounds or revenue, and has limited named-customer visibility (Beard Medical and BHT Optometry).

Name

HEART EYE DIAGNOSTICS LIMITED

Legal name

HeartEye

Website

https://hearteye.co.uk

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

HeartEye (HEART EYE DIAGNOSTICS LIMITED) is a UK-based private medical AI company whose Dr. Noon platform performs dual retinal screening for cardiovascular risk and eye disease from routine fundus images, serving optometrists, GPs, and primary care networks via a CE-marked, MHRA-approved cloud SaaS.

Ownership category

akta.pro rank

Product category

Medical AI Diagnostic Software

NAICS

Diagnostic Imaging Centers (621512)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB)

Keywords

• AI retinal screening
• Cardiovascular risk assessment
• Retinal disease detection
• Fundus imaging software
• Preventive health screening

Headquarters

HQ city

Edgware

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. AI Screening Platform Subscription: Healthcare and eye care professionals subscribe to access Dr. Noon platform for AI-powered retinal screening. Implementation includes account setup, training, and ongoing support.
2. Per-Screening Fees: Revenue generated per retinal scan analysed by the AI platform. Fast, cost-effective screening suitable for high-throughput everyday care without requiring specialists or labs.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Heart Eye Diagnostics develops and distributes Dr. Noon, a cloud-based AI retinal screening platform that analyses standard fundus photographs to deliver dual insights in approximately one minute: cardiovascular disease risk assessment with CACS-aligned Low/Moderate/High risk banding, and detection of retinal abnormalities including glaucoma, age-related macular degeneration, diabetic retinopathy, and cataracts. The platform is sold to healthcare professionals (GPs, primary care networks, hospitals) and eye care professionals (optometrists, optical practices) as a subscription service that integrates with existing fundus cameras without requiring new specialist equipment, radiation, or contrast agents.

Product overview

Dr. Noon is an AI-powered retinal screening platform comprising two main modules: Dr. Noon HEART for cardiovascular risk assessment and Dr. Noon EYE for retinal disease detection. The platform analyzes routine fundus images to deliver instant, validated insights without requiring new clinical processes or heavy infrastructure. Separate solutions are offered for Healthcare Professionals (HCP) and Eye Care Professionals (ECP), enabling opportunistic screening, chronic disease management support, and population health programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Dr. Noon Core AI-powered retinal screening platform that delivers dual insights from a single routine fundus image: eye disease screening for key retinal findings (diabetic retinopathy, AMD, glaucoma, cataract) and instant cardiovascular risk assessment with validated performance comparable to CT calcium scoring. Targeted at healthcare and eye care professionals.

Quantifiable outcome

• 96% diagnostic accuracy in detecting retinal disease, comparable to real ophthalmologists
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• UK BiobankcoreTechnology or IntegrationUK Biobank provides large-scale retinal imaging data used to train and validate Dr. Noon's deep learning algorithms. The database of several hundred thousand patients enables robust algorithm development across diverse ethnicities.
• CMERC-HI (Cardiovascular Metabolic Diseases Research Center - HI)coreStrategic or Co-development PartnerCMERC-HI conducted pivotal clinical trial of the deep-learning-based retinal biomarker (Reti-CVD) for cardiovascular disease prediction, published in JAMIA 2023.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Topcon Healthcare: Topcon Healthcare is a major ophthalmic device manufacturer that has expanded into AI-powered screening including retinal imaging and disease detection (e.g., Harmony, iScreen). Broad incumbent with overlapping AI retinal screening capabilities via integrated fundus camera hardware.
• Optos (Nikon Healthcare): Optos produces ultra-widefield retinal imaging devices widely used in optometry, with software enhancements for disease detection. Comparable as an incumbent whose imaging infrastructure and screening workflows overlap with HeartEye's optometry-focused deployment model.
• HeartFlow: HeartFlow provides AI-driven non-invasive coronary CT angiography analysis for cardiovascular disease diagnosis. Comparable as a broad incumbent in AI cardiovascular imaging, addressing the same CVD risk assessment problem HeartEye targets but using CT rather than retinal imaging.
• ZEISS Medical Technology: ZEISS is a global ophthalmic devices and imaging incumbent (Cirrus OCT, Clarus fundus cameras) with growing investments in AI-enabled diagnostics. Comparable as a broad incumbent offering imaging hardware plus emerging AI screening workflows in optometry and ophthalmology.

Others

• Sightpath Medical / Vanguard Medical Concepts (UK optometry AI services): UK optometry-focused clinical service and AI imaging providers. Listed as adjacent ecosystem participants serving the same optometry channel where HeartEye distributes Dr. Noon, though exact comparable UK-native peer is difficult to identify with confidence; included only as a placeholder for the UK optometry AI services category.

Direct peers

• AEYE Health: AEYE Health provides FDA-cleared AI for autonomous diabetic retinopathy screening from retinal fundus images, targeting primary care and optometry. Directly comparable to HeartEye's Dr. Noon EYE module in product, customer base, and screening workflow.
• Eyenuk: Eyenuk develops EyeArt, an FDA-cleared AI system for autonomous diabetic retinopathy screening. Directly comparable to HeartEye's EYE module in both product functionality and target customer base of optometrists and primary care.
• Digital Diagnostics (IDx): Digital Diagnostics (formerly IDx) is the first FDA-cleared autonomous AI diagnostic platform (IDx-DR) for diabetic retinopathy screening at the point of care. Directly competes with HeartEye in AI retinal disease detection in primary care settings.
• Cleerly: Cleerly applies AI to coronary CT angiography for plaque-based cardiovascular risk assessment. Comparable to HeartEye's HEART module as a CVD risk stratification AI play targeting preventive cardiology use cases, though using a different imaging modality.

Emerging players

• Elucid Bio: Elucid Bio develops AI-driven cardiovascular imaging analysis for atherosclerosis characterization. Emerging player in the AI CVD risk stratification space, comparable to HeartEye's HEART module in target use case and clinical positioning, though using imaging rather than retinal biomarkers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/heart-eye

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HEART EYE DIAGNOSTICS LIMITED